159 related articles for article (PubMed ID: 8564348)
1. Treatment of tumour-induced hypercalcaemia in advanced breast cancer patients with three different doses of disodium pamidronate adapted to the initial level of calcaemia.
Nesković-Konstantinović Z; Mitrović L; Petrović J; Stamatović L; Ristović Z
Support Care Cancer; 1995 Nov; 3(6):422-4. PubMed ID: 8564348
[TBL] [Abstract][Full Text] [Related]
2. Treatment of tumour-induced hypercalcaemia with the bisphosphonate pamidronate: dose-response relationship and influence of tumour type.
Body JJ; Dumon JC
Ann Oncol; 1994 Apr; 5(4):359-63. PubMed ID: 8075034
[TBL] [Abstract][Full Text] [Related]
3. Parathyroid hormone-related protein(50-69) and response to pamidronate therapy for tumour-induced hypercalcaemia.
Dodwell DJ; Abbas SK; Morton AR; Howell A
Eur J Cancer; 1991; 27(12):1629-33. PubMed ID: 1782072
[TBL] [Abstract][Full Text] [Related]
4. Pamidronate. A review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget's disease of bone.
Coukell AJ; Markham A
Drugs Aging; 1998 Feb; 12(2):149-68. PubMed ID: 9509293
[TBL] [Abstract][Full Text] [Related]
5. Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia.
Gurney H; Grill V; Martin TJ
Lancet; 1993 Jun; 341(8861):1611-3. PubMed ID: 8099988
[TBL] [Abstract][Full Text] [Related]
6. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy.
Purohit OP; Radstone CR; Anthony C; Kanis JA; Coleman RE
Br J Cancer; 1995 Nov; 72(5):1289-93. PubMed ID: 7577484
[TBL] [Abstract][Full Text] [Related]
7. Impact of chemotherapy on hypercalcemia in breast and lung cancer patients.
Hassan BA; Yusoff ZB; Hassali MA; Othman SB; Weiderpass E
Asian Pac J Cancer Prev; 2012; 13(9):4373-8. PubMed ID: 23167346
[TBL] [Abstract][Full Text] [Related]
8. Metastatic bone disease and tumour-induced hypercalcaemia: the role of bisphosphonates.
Heatley S
Int J Palliat Nurs; 2001 Jun; 7(6):301-2, 304-7. PubMed ID: 12066026
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group.
Hortobagyi GN; Theriault RL; Porter L; Blayney D; Lipton A; Sinoff C; Wheeler H; Simeone JF; Seaman J; Knight RD
N Engl J Med; 1996 Dec; 335(24):1785-91. PubMed ID: 8965890
[TBL] [Abstract][Full Text] [Related]
10. Decreased efficacy of bisphosphonates for recurrences of tumor-induced hypercalcemia.
Body JJ; Louviaux I; Dumon JC
Support Care Cancer; 2000 Sep; 8(5):398-404. PubMed ID: 10975689
[TBL] [Abstract][Full Text] [Related]
11. Tumor 'flare' hypercalcemia--an additional indication for bisphosphonates?
Nikolic-Tomasević Z; Jelic S; Popov I; Radosavljević D; Mitrović L
Oncology; 2001; 60(2):123-6. PubMed ID: 11244326
[TBL] [Abstract][Full Text] [Related]
12. Analysis of survival following treatment of tumour-induced hypercalcaemia with intravenous pamidronate (APD).
Ling PJ; A'Hern RP; Hardy JR
Br J Cancer; 1995 Jul; 72(1):206-9. PubMed ID: 7599053
[TBL] [Abstract][Full Text] [Related]
13. [Pamidronate in the treatment of tumor-associated hypercalcemia].
Pecherstorfer M; Janisch S; Marosi C; Wogritsch C; Bosse C; Schratzberger W; Gerber E; Fortelny A; Lenzhofer R; Rainer H
Klin Wochenschr; 1991 Oct; 69(15):690-5. PubMed ID: 1795492
[TBL] [Abstract][Full Text] [Related]
14. [Diphosphonates in the treatment of hypercalcemia].
Delmas PD; Meunier PJ
Rev Med Interne; 1984 Nov; 5(4):363-6. PubMed ID: 6240753
[TBL] [Abstract][Full Text] [Related]
15. [Two cases of malignancy-associated hypercalcemia from bone metastases of breast cancer successfully treated with combination therapy using pamidronate and calcitonin].
Kusama M; Kaise H; Nakayama S; Ota D; Aoki T; Koyanagi Y; Matsunaga T; Nakamura Y
Gan To Kagaku Ryoho; 2000 May; 27(5):763-6. PubMed ID: 10832449
[TBL] [Abstract][Full Text] [Related]
16. [Osteolytic metastases of breast cancer and biphosphonates].
Lortholary A; Alleaume C; Pein F; Larra F
Rev Med Interne; 1992; 13(3):238-42. PubMed ID: 1410908
[TBL] [Abstract][Full Text] [Related]
17. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages.
Nussbaum SR; Younger J; Vandepol CJ; Gagel RF; Zubler MA; Chapman R; Henderson IC; Mallette LE
Am J Med; 1993 Sep; 95(3):297-304. PubMed ID: 8368227
[TBL] [Abstract][Full Text] [Related]
18. Intravenous pamidronate for hypercalcemia of primary hyperparathyroidism.
Tal A; Graves L
South Med J; 1996 Jun; 89(6):637-40. PubMed ID: 8638211
[TBL] [Abstract][Full Text] [Related]
19. An audit of the management of malignant hypercalcaemia.
Gerrard GE; Dodwell DJ; Vail A; Watters J; Overend MA
Clin Oncol (R Coll Radiol); 1996; 8(1):39-42. PubMed ID: 8688360
[TBL] [Abstract][Full Text] [Related]
20. Pamidronate (Aredia, Ciba) in malignant hypercalcaemia.
MacConnachie AM
Intensive Crit Care Nurs; 1997 Feb; 13(1):58-9. PubMed ID: 9095884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
